Rochefort P, et al. - Researchers examined metastatic pancreatic ductal adenocarcinoma (mPDAC) patients who survived more than 18 months, to define “long-term survivor” population in mPDAC. They also investigated factors that might influence survival. A control cohort was also used which was matched on age, sex, performance status, stage at diagnosis, primary tumor localization, treatment, and liver metastasis. This study included 94 patients, 47 in each cohort. The long-term survivor group and the control group had a median overall survival of 26.87 months and 9.79 months, respectively. As concluded by experts, long-term survival (≥18 months) can be achieved in 2018 by a significant subset of patients with mPDAC. A significant prognostic factor related to long-term survival in mPDAC was low neutrophil-to-lymphocyte ratio.